150 results on '"Girard, Philippe"'
Search Results
2. Preventative and curative treatment of venous thromboembolic disease in cancer patients
3. Traduction et republication de : « Événements thromboemboliques artériels liés au cancer »
4. Toussaint Louverture, the Cultivator System, and Haiti’s Independence (1798–1804)
5. Le Marronage et la révolte de 1791 : Le Cas de la plantation Bréda du Haut-du-Cap
6. Plasma tissue factor activity in lung cancer patients predicts venous thromboembolism and poor overall survival
7. Central venous catheter associated upper extremity deep vein thrombosis in cancer patients: Diagnosis and therapeutic management
8. Anticoagulant treatment of cancer-associated thromboembolism
9. Treatment of cancer-associated venous thromboembolism in patients under palliative care
10. Recurrent venous thromboembolism in anticoagulated cancer patients: Diagnosis and treatment
11. French guidelines for the treatment of cancer-associated venous thromboembolism - 2023 update
12. Pulmonary embolism diagnostic strategies in patients with COPD exacerbation: Post-hoc analysis of the PEP trial
13. Selecting risk response strategies to minimize human errors in a design project for factories of the future
14. Haiti, Slavery and the War in the Caribbean
15. Frequency and predictors for chronic thromboembolic pulmonary hypertension after a first unprovoked pulmonary embolism: Results from PADIS studies
16. Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial
17. Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis
18. Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial
19. Surgical or medical strategy for locally-advanced, stage IIIA/B-N2 non-small cell lung cancer: Reproducibility of decision-making at a multidisciplinary tumor board
20. LiSA: an assisted literature search pipeline for detecting serious adverse drug events with deep learning
21. Marlene L. Daut Awakening the Ashes. An Intellectual History of the Haitian Revolution. University of North Carolina Press, Chapel Hill (NC) 2023. xxi, 415 pp. Ill. Maps. $99.00. (Paper: $34.95; E-book: $27.99.)
22. Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies
23. Anticoagulant treatment of cancer-associated thromboembolism
24. Central venous catheter associated upper extremity deep vein thrombosis in cancer patients: diagnosis and therapeutic management
25. Treatment of cancer-associated venous thromboembolism in patients under palliative care
26. Recurrent venous thromboembolism in anticoagulated cancer patients: diagnosis and treatment
27. Interactions of netrin-1 through its glycosylation sites immobilize Deleted in Colorectal Cancer (DCC) by favoring its constitutive clustering
28. Treatment of cancer-associated venous thromboembolism. 2023 update of the French guidelines Traitement de la maladie veineuse thromboembolique au cours du cancer Mise à jour Avril 2023
29. Suspected pulmonary embolism in the emergency department: over-, under- and/or mis-testing?
30. A Secret Among the Blacks: Slave Resistance Before the Haitian Revolution, by John D. Garrigus.
31. Pulmonary embolism diagnostic strategies in patients with COPD exacerbation: post-hoc analysis of the PEP trial
32. Enoxaparin versus Placebo to Prevent Symptomatic Venous Thromboembolism in Hospitalized Older Adult Medical Patients
33. Accuracy and interrater agreement of death event adjudications by physician trainees: validation of the ISTH definition of pulmonary embolism-related death in an autopsy cohort
34. Artificial intelligence and real-world data for drug and food safety – A regulatory science perspective
35. Artificial intelligence and real-world data for drug and food safety - A regulatory science perspective
36. Supplementary Table 1 from A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma
37. Supplementary Methods and Figure Legend from A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma
38. Supplementary Figure 1 from A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma
39. Supplementary Table 3 from Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC
40. Supplementary Figure 2 from A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma
41. Supplementary Methods from Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC
42. Supplementary Table 2 from A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma
43. Supplementary Table 2 from Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC
44. Supplementary Table 3 from A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma
45. Supplementary Figure 1 from Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC
46. Supplementary Figure 3 from A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma
47. Supplementary Table 4 from A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma
48. Supplementary Table 1 from Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC
49. Data from Cisplatin Resistance Associated with PARP Hyperactivation
50. Supplementary Table 1, Figures 1 - 8 from Cisplatin Resistance Associated with PARP Hyperactivation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.